News and Announcements
MAAS MVP
- Published June 08, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
MAAS Solutions has reached the milestone of the product during COVID-19 and has completed their PPM module and interactive calendar with the asset manager APP. The new module would allow the clients and building operators to program their Preventive Maintenance schedules based on their needs and building compliance requirement as well as clearly tag the schedules with their risk and compliance profile. They are in discussions with clients for starting the demo stages within the real physical sites testing.
About MAAS Solutions
MAAS Solutions, specialised in Asset Optimisation and Asset Life Cycle Management has developed a unique multi-layered approach that incorporates asset identification, condition auditing, functional assessment, degradation modelling and strategic asset planning.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
